Current Rheumatology Reports

, Volume 10, Issue 4, pp 257–258 | Cite as

Is individualized medicine on the horizon for lupus?

Invited Commentary


  1. 1.
    International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, et al.: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40: 204–210. (Comment in: Nat Genet 08, 40: 131–132.)PubMedCrossRefGoogle Scholar
  2. 2.
    Hom G, Graham RR, Modrek B, et al.: Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358: 900–909.PubMedCrossRefGoogle Scholar
  3. 3.
    Katsiari CG, Liossis SN, Souliotis VL, et al.: Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus Clin Immunol 2002, 103: 54–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Blanco P, Palucka AK, Gill M, et al.: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294: 1540–1543.PubMedCrossRefGoogle Scholar
  5. 5.
    Liou LB: Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001, 19: 515–523.PubMedGoogle Scholar
  6. 6.
    Csiszar A, Nagy G, Gergely P, et al.: Increased interferongamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000, 122: 464–470.PubMedCrossRefGoogle Scholar
  7. 7.
    Grondal G, Gunnarsson I, Ronnelid J, et al.: Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18: 565–570.PubMedGoogle Scholar
  8. 8.
    Liu TF, Jones BM: Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998, 10: 140–147.PubMedCrossRefGoogle Scholar
  9. 9.
    Stohl W: B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002, 4: 345–350.PubMedCrossRefGoogle Scholar
  10. 10.
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry, systemic lupus erythematosus-developing drugs for treatment. Accessible at Accessed June 6, 2008.

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Clinical Pharmacology Research ProgramOklahoma Medical Research FoundationOklahoma CityUSA

Personalised recommendations